-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $18 Price Target

Benzinga·03/11/2026 10:48:37
Listen to the news
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $18 price target.